Reduces intraocular pressure (IOP). ANDA 217387, held by Gland Pharma. Latanoprostene Bunod.
As of Nov 21, 2026, ANDA 217387 (Latanoprostene Bunod), held by Gland Pharma, was first approved by FDA on Apr 29, 2025, with 0 approved supplements and 0 published complete response letters.
Latanoprostene bunod ophthalmic solution, 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 29, 2025 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Latanoprostene Bunod0.024% · solution/drops;ophthalmic | Latanoprostene Bunod | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters